Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK

an observational study

Carolynne J Vaizey, Peter R Gibson, Christopher M Black, Rebecca J Nicholls, Adele R Weston, Daniel R Gaya, Shaji Sebastian, Ian Shaw, Stephen Lewis, Stuart Bloom, John N Gordon, Amanda Beale, Ian Arnott, Simon Campbell, Tao Fan

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background Ulcerative colitis is a lifelong, chronic, relapsing-remitting disease. Objective To assess the relationship between ulcerative colitis disease status and patient quality of life, and to determine the impact of ulcerative colitis on healthcare costs and work productivity, in the UK. Methods Clinicians assessed 173 adult patients’ current disease status at a single study visit using the partial Mayo (pMayo) instrument. Patients completed the Euro Quality of Life 5-dimension, 5-level (EQ-5D-5L) questionnaire, the Work Productivity and Activity Impairment (WPAI) questionnaire. Healthcare resource use was determined from questionnaires and from patients’ medical charts. Results Patients in remission had a significantly higher EQ-5D-5L scores (mean (SD) 0.86 (0.15)) than patients with active disease (0.71 (0.20); p<0.001). Patients with mild disease had significantly higher mean (SD) EQ-5D-5L scores than patients with moderate/severe disease: 0.77 (0.11) and 0.66 (0.24), respectively (p<0.001). The mean percent productivity impairment was greater for patients with active disease than for patients in remission on all items of the WPAI questionnaire: 24.6% vs 1.8% for work time missed, 34.1% vs 12.9% for impairment while working, 40.8% vs 14.4% for overall work impairment and 42.7% vs 13.0% for activity impairment (p<0.001 for all comparisons). The mean (SD) total cost of healthcare for ulcerative colitis in the prior 3 months was £1211 (1588). Conclusions When compared with patients in remission, patients with active ulcerative colitis have significantly worse quality of life and significantly more work impairment. The healthcare costs of ulcerative colitis are considerable.
Original languageEnglish
Pages (from-to)183-189
Number of pages7
JournalFrontline Gastroenterology
Volume5
Issue number3
DOIs
Publication statusPublished - 2014

Cite this

Vaizey, Carolynne J ; Gibson, Peter R ; Black, Christopher M ; Nicholls, Rebecca J ; Weston, Adele R ; Gaya, Daniel R ; Sebastian, Shaji ; Shaw, Ian ; Lewis, Stephen ; Bloom, Stuart ; Gordon, John N ; Beale, Amanda ; Arnott, Ian ; Campbell, Simon ; Fan, Tao. / Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK : an observational study. In: Frontline Gastroenterology. 2014 ; Vol. 5, No. 3. pp. 183-189.
@article{4dab81705a284cd89ee2f3c91473e6a1,
title = "Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: an observational study",
abstract = "Background Ulcerative colitis is a lifelong, chronic, relapsing-remitting disease. Objective To assess the relationship between ulcerative colitis disease status and patient quality of life, and to determine the impact of ulcerative colitis on healthcare costs and work productivity, in the UK. Methods Clinicians assessed 173 adult patients’ current disease status at a single study visit using the partial Mayo (pMayo) instrument. Patients completed the Euro Quality of Life 5-dimension, 5-level (EQ-5D-5L) questionnaire, the Work Productivity and Activity Impairment (WPAI) questionnaire. Healthcare resource use was determined from questionnaires and from patients’ medical charts. Results Patients in remission had a significantly higher EQ-5D-5L scores (mean (SD) 0.86 (0.15)) than patients with active disease (0.71 (0.20); p<0.001). Patients with mild disease had significantly higher mean (SD) EQ-5D-5L scores than patients with moderate/severe disease: 0.77 (0.11) and 0.66 (0.24), respectively (p<0.001). The mean percent productivity impairment was greater for patients with active disease than for patients in remission on all items of the WPAI questionnaire: 24.6{\%} vs 1.8{\%} for work time missed, 34.1{\%} vs 12.9{\%} for impairment while working, 40.8{\%} vs 14.4{\%} for overall work impairment and 42.7{\%} vs 13.0{\%} for activity impairment (p<0.001 for all comparisons). The mean (SD) total cost of healthcare for ulcerative colitis in the prior 3 months was £1211 (1588). Conclusions When compared with patients in remission, patients with active ulcerative colitis have significantly worse quality of life and significantly more work impairment. The healthcare costs of ulcerative colitis are considerable.",
author = "Vaizey, {Carolynne J} and Gibson, {Peter R} and Black, {Christopher M} and Nicholls, {Rebecca J} and Weston, {Adele R} and Gaya, {Daniel R} and Shaji Sebastian and Ian Shaw and Stephen Lewis and Stuart Bloom and Gordon, {John N} and Amanda Beale and Ian Arnott and Simon Campbell and Tao Fan",
year = "2014",
doi = "10.1136/flgastro-2013-100409",
language = "English",
volume = "5",
pages = "183--189",
journal = "Frontline Gastroenterology",
issn = "2041-4137",
publisher = "BMJ Publishing Group",
number = "3",

}

Vaizey, CJ, Gibson, PR, Black, CM, Nicholls, RJ, Weston, AR, Gaya, DR, Sebastian, S, Shaw, I, Lewis, S, Bloom, S, Gordon, JN, Beale, A, Arnott, I, Campbell, S & Fan, T 2014, 'Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: an observational study', Frontline Gastroenterology, vol. 5, no. 3, pp. 183-189. https://doi.org/10.1136/flgastro-2013-100409

Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK : an observational study. / Vaizey, Carolynne J; Gibson, Peter R; Black, Christopher M; Nicholls, Rebecca J; Weston, Adele R; Gaya, Daniel R; Sebastian, Shaji ; Shaw, Ian; Lewis, Stephen; Bloom, Stuart ; Gordon, John N; Beale, Amanda ; Arnott, Ian ; Campbell, Simon; Fan, Tao.

In: Frontline Gastroenterology, Vol. 5, No. 3, 2014, p. 183-189.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK

T2 - an observational study

AU - Vaizey, Carolynne J

AU - Gibson, Peter R

AU - Black, Christopher M

AU - Nicholls, Rebecca J

AU - Weston, Adele R

AU - Gaya, Daniel R

AU - Sebastian, Shaji

AU - Shaw, Ian

AU - Lewis, Stephen

AU - Bloom, Stuart

AU - Gordon, John N

AU - Beale, Amanda

AU - Arnott, Ian

AU - Campbell, Simon

AU - Fan, Tao

PY - 2014

Y1 - 2014

N2 - Background Ulcerative colitis is a lifelong, chronic, relapsing-remitting disease. Objective To assess the relationship between ulcerative colitis disease status and patient quality of life, and to determine the impact of ulcerative colitis on healthcare costs and work productivity, in the UK. Methods Clinicians assessed 173 adult patients’ current disease status at a single study visit using the partial Mayo (pMayo) instrument. Patients completed the Euro Quality of Life 5-dimension, 5-level (EQ-5D-5L) questionnaire, the Work Productivity and Activity Impairment (WPAI) questionnaire. Healthcare resource use was determined from questionnaires and from patients’ medical charts. Results Patients in remission had a significantly higher EQ-5D-5L scores (mean (SD) 0.86 (0.15)) than patients with active disease (0.71 (0.20); p<0.001). Patients with mild disease had significantly higher mean (SD) EQ-5D-5L scores than patients with moderate/severe disease: 0.77 (0.11) and 0.66 (0.24), respectively (p<0.001). The mean percent productivity impairment was greater for patients with active disease than for patients in remission on all items of the WPAI questionnaire: 24.6% vs 1.8% for work time missed, 34.1% vs 12.9% for impairment while working, 40.8% vs 14.4% for overall work impairment and 42.7% vs 13.0% for activity impairment (p<0.001 for all comparisons). The mean (SD) total cost of healthcare for ulcerative colitis in the prior 3 months was £1211 (1588). Conclusions When compared with patients in remission, patients with active ulcerative colitis have significantly worse quality of life and significantly more work impairment. The healthcare costs of ulcerative colitis are considerable.

AB - Background Ulcerative colitis is a lifelong, chronic, relapsing-remitting disease. Objective To assess the relationship between ulcerative colitis disease status and patient quality of life, and to determine the impact of ulcerative colitis on healthcare costs and work productivity, in the UK. Methods Clinicians assessed 173 adult patients’ current disease status at a single study visit using the partial Mayo (pMayo) instrument. Patients completed the Euro Quality of Life 5-dimension, 5-level (EQ-5D-5L) questionnaire, the Work Productivity and Activity Impairment (WPAI) questionnaire. Healthcare resource use was determined from questionnaires and from patients’ medical charts. Results Patients in remission had a significantly higher EQ-5D-5L scores (mean (SD) 0.86 (0.15)) than patients with active disease (0.71 (0.20); p<0.001). Patients with mild disease had significantly higher mean (SD) EQ-5D-5L scores than patients with moderate/severe disease: 0.77 (0.11) and 0.66 (0.24), respectively (p<0.001). The mean percent productivity impairment was greater for patients with active disease than for patients in remission on all items of the WPAI questionnaire: 24.6% vs 1.8% for work time missed, 34.1% vs 12.9% for impairment while working, 40.8% vs 14.4% for overall work impairment and 42.7% vs 13.0% for activity impairment (p<0.001 for all comparisons). The mean (SD) total cost of healthcare for ulcerative colitis in the prior 3 months was £1211 (1588). Conclusions When compared with patients in remission, patients with active ulcerative colitis have significantly worse quality of life and significantly more work impairment. The healthcare costs of ulcerative colitis are considerable.

U2 - 10.1136/flgastro-2013-100409

DO - 10.1136/flgastro-2013-100409

M3 - Article

VL - 5

SP - 183

EP - 189

JO - Frontline Gastroenterology

JF - Frontline Gastroenterology

SN - 2041-4137

IS - 3

ER -